In Vivo Cell Therapy, IIT and the Nordic Landscape

Cell therapy is entering a new phase. The question is no longer whether engineered immune cells can deliver clinical value, but how they can be developed, manufactured, and delivered at a scale that meaningfully expands patient access.

In vivo, CAR-T is attracting attention because it could shift part of the engineering process from the manufacturing facility to the patient's body. Instead of collecting, modifying and reinfusing cells, the therapeutic payload is delivered directly so immune cells can be programmed in vivo. This could simplify development, reduce logistical burden, and support more scalable delivery models.

For the Nordic life science community, the opportunity is highly relevant. Strong academic science, advanced healthcare systems, ATMP expertise and a culture of collaboration position the region to generate innovative ideas and explore how emerging cell therapy models can move responsibly toward clinical use.

But innovation alone will not be enough. To move from promise to clinical reality, developers must address manufacturability, delivery strategy, regulatory expectations, and commercial viability from the earliest stages. The strongest programmes will connect compelling biology with practical development plans.

This also matters to investors. Venture capital interest in advanced therapies is increasingly shaped by questions of scale, cost of goods and whether a platform can progress beyond early proof of concept. Differentiated science remains essential, but it must be matched by a credible route to manufacture and adoption.

Manufacturing readiness is central to that equation. Whether programmes use viral or non-viral delivery, plasmid DNA often plays a foundational role in vector production, RNA-based approaches, quality, scalability, and regulatory success. Early decisions on plasmid design, supply and quality can determine how efficiently a platform advance.

As requirements expand into analytical development, stability testing, documentation and GMP manufacturing, fragmented supplier models can add complexity. Integrated CDMO support can help in vivo CAR-T developers align development and manufacturing strategy earlier, reduce handoff risk and maintain momentum.

The global development landscape is also evolving with Asia becoming an important setting for early clinical translation. China's State Council Decree No. 818, introduced on the 1st of May 2026, has been highlighted as driving an even more rigorous adoption of preclinical evidence, including animal testing, before patient enrolment to enforce higher standards of transparency and oversight and has markedly increased the scientific and regulatory robustness of China's IIT framework.

For Nordic innovators, this should not be viewed simply as outsourcing. It points to a broader model of global evidence generation, where clinical infrastructure, experienced investigators and patient access can help produce early data that support international development plans and future investment conversations.

IITs can be especially valuable here. They give academic and clinical researchers a platform to test novel strategies and generate translational evidence before programmes move into sponsor-led development, helping researcher-driven innovation progress more quickly.

For advanced therapy developers, this creates a need for integrated capabilities across plasmid DNA, viral vectors, mRNA, cell, and gene therapy development, IITs, and GMP manufacturing. Connecting scientific ambition with execution can help build strategies that are credible from discovery through clinical translation.

In vivo, CAR-T may complement, reshape, or redefine existing cell therapy models. Whatever the outcome, its future will depend on more than breakthrough science. It will depend on whether the field can turn promise into practice through strategies built for scale, quality, and real-world patient access.

To learn more about in vivo CAR-T development strategies and ProBio's approach towards IITs, visit In Vivo CAR-T Hub